Merit Financial Group’s Adaptive Biotechnologies ADPT Stock Holding History

Merit Financial Group’s Portfolio ADPT Stock Details ADPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$479K	Buy	+22,330	New	+$342K	﹤0.01%	1522

Other funds holding ADPT

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

PCM

Peregrine Capital Management Minneapolis, Minnesota $3.08B AUM 29.51% 1-Year Est. Return

YIH

Y-Intercept (HK) Hong Kong $5.05B AUM 17.89% 1-Year Est. Return

EWM

Edge Wealth Management New York $594M AUM 24.92% 1-Year Est. Return

Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return

Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return

Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return

GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return

NWAG

Net Worth Advisory Group Sandy, Utah $397M AUM 29.92% 1-Year Est. Return

Merit Financial Group's ADPT Position: Q2 2026 in Review

Merit Financial Group opened a new position in Adaptive Biotechnologies (ADPT) in Q2 2026: 22,330 shares worth $479K. The stake represents ﹤0.01% of the portfolio and ranks #1522 among its holdings.

22 funds tracked by Wall St. Rank hold ADPT as of Q2 2026.

Merit Financial Group held 22,330 shares of Adaptive Biotechnologies worth $479K as of Q2 2026.
Adaptive Biotechnologies was a new Merit Financial Group position in Q2 2026.
Adaptive Biotechnologies made up ﹤0.01% of Merit Financial Group's portfolio in Q2 2026, its #1522 holding.
22 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2026.

Based on Merit Financial Group's 13F filing for Q2 2026, filed 17 Jul 2026.